First-generation injectable MS DMTs - Beta interferons and glatiramer acetate were the first MS disease modifying therapies, FDA-approved in the 1990s. They are only moderately effective compared to more modern MS treatment options, but they are felt to be generally safe and well-tolerated. Injection-related side effects are common.
Date
2023-03
References
1. Birnbaum, G: Multiple Sclerosis. In: Bielekova B, Birnbaum G, Lisak RP, editors. Neuroimmunology. Oxford: Contemporary Neurology Series; 2019. 2. Fox RJ, Rae-Grant AD, Bethoux F. Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation. Springer: Demos Medical; 2019. 3. Kappos L, Fox RJ, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial. JAMA Neurol. 2021;78(5):558-567. Doi:10.1001/jamaneurol.2021.0405. 4. Giovannoni G, Comi G, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med 2010;362:416-26. Doi: 10.1056/NEJMoa0902533. 5. Ryerson LZ, Li X, Goldberg JD, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm 2020;7:e672. Doi:10.1212/NXI.0000000000000672.
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2023 North American Neuro-Ophthalmology Society Annual Meeting
